AlphaCentric Launches the AlphaCentric LifeSci Healthcare Fund Focused on Biotech and Healthcare Sectors

Huntington, NY, January 29, 2020 –  AlphaCentric, the mutual fund company that provides investors access to unique investment strategies with a nuanced approach to traditional and non-traditional asset classes, today announced the launch of the AlphaCentric LifeSci Healthcare Fund (LYFIX). Focused on biotech and healthcare equities, this Fund leverages the expertise of more than 20 PhDs and MDs and the scientific and investment backgrounds of the portfolio management team to identify companies with groundbreaking scientific research that the team believes can achieve the Fund’s investment objective of long-term capital appreciation. The Fund is sub-advised by LifeSci Fund Management.

LYFIX’s is designed to outperform other funds in its sector by leveraging this unique combination of scientific and investment experience to invest in the life sciences and healthcare sectors. The Fund’s investment strategy focuses on science-driven biotechnology and pharmaceutical companies that address high, unmet medical needs. Equity positions are concentrated on the following categories: biotech and pharmaceutical, health care facilities and services and medical equipment and device industries.

The portfolio is managed by Mark Charest, PhD. A former practicing molecular chemist and inventor on eight drug patents turned Wall Street trader, Charest has spent more than a decade investing in healthcare. He received a PhD and M.S. in chemistry and chemical biology from Harvard University and was a National Science Foundation Graduate Research Fellow. His background provides a specialized knowledge and acute ability to assess investment opportunities in this sector.

“Capital flowing into the healthcare and biotech sectors has exploded, boosted by promising advances in genomics and other scientific breakthroughs,” said Mark Kamies, co-founder of AlphaCentric. “The tremendous opportunity and challenge for investors is to figure out which companies possess truly game changing research, products and services that will result in strong stock performance. When new science and biotechnology are introduced to the market, it takes a specialized knowledge to assess its future and viability. We are tapping such expertise with Mark Charest and the LifeSci team, and are proud to offer their expertise and this focused strategy to investors.”

The introduction of LYFIX coincides with an opportunistic time for both the healthcare and biotech sectors. Both are experiencing growth, fueled by a number of factors such as unprecedented science- and technology-driven innovation, sustained pace of FDA approvals, a strong financing environment, increased spending and investor demand for ESG strategies. The Fund’s investment strategy is designed to track and identify these on-going opportunities and take portfolio positions accordingly.

The AlphaCentric LifeSci Healthcare Fund will trade under the tickers LYFIX, LYFAX and LYFCX. For more information on AlphaCentric and its family of funds, please visit:

About AlphaCentric Funds

AlphaCentric Funds provides investors access to unique investment strategies with a nuanced approach to traditional and non-traditional asset classes. Founded in 2014, the firm currently offers eight different strategies in mutual fund format. AlphaCentric’s investment management teams hold long-term track records and are leading experts in their particular fields, providing top-down thought leadership that translates into forward-thinking investing. The firm has partnered with a number of notable investment managers to offer niche, active strategies focused on; alternative income, above average growth and risk management. To learn more about AlphaCentric and its family of funds, please visit:

Important Risk Information

The Fund is a new mutual fund and has a limited history of operations for investors to evaluate. The fund may be non-diversified and the value and/or volatility of a single issuer could have a greater impact on fund performance. The Fund may be susceptible to an increased risk of loss due to adverse occurrences affecting the Fund more than the market as a whole, because the Funds investments are concentrated. Some securities held by the Fund may be difficult to sell, or illiquid, particularly during times of market turmoil. The Funds’ can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The funds’ can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Further, these companies are dependent on patent protection, and the expiration of patents may adversely affect the profitability of the companies. The Fund invests in IPOs at the time of the initial public offering and in post-IPO trading. IPOs are often subject to extreme price volatility and speculative trading. The ETFs in which the fund invests are subject to advisory fees and other expenses and as a result the cost of investing in the fund will be higher than the cost of investing directly in the underlying funds. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. All investments involve risks, including possible loss of principal, there is no assurance that the Fund will achieve its investment objective.

Investors should carefully consider the investment objectives, risks, charges and expenses of the AlphaCentric Funds. This and other important information about the Fund is contained in the prospectus, which can be obtained by calling 844-ACFUNDS (844-223-8637) or at The prospectus should be read carefully before investing. The AlphaCentric Funds are distributed by Northern Lights Distributors, LLC, member FINRA/SIPC. AlphaCentric Advisors LLC is not affiliated with Northern Lights Distributors, LLC.